ASH 2022 | The role of mass spectrometry in response assessment in patients with AL amyloidosis
Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, comments on the benefits of using mass spectrometry (MS) to assess response to treatment in patients with AL amyloidosis, explaining that this technique can accurately detect monoclonal light chains, and that achieving MS-negativity can predict a good response to treatment better than standard methods. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen: Honoraria, Other: Travel Support; Attralus: Honoraria; Takeda: Other: Travel Support; Alexion: Honoraria, Other: Travel Support; GSK: Honoraria.
